Vismodegib in treatment of reccurence, locally advanced basal cell carcinoma
نویسندگان
چکیده
Bazaliom je nejÄastÄjĹĄĂ nemelanomovĂ˝ koĹžnĂ nĂĄdor vychĂĄzejĂcĂ z bazĂĄlnĂch bunÄk epidermis, charakterizovanĂ˝ pomalĂ˝m a destruktivnĂm rĹŻstem. NejÄastÄjĹĄĂ terapeutickou metodou chirurgickĂĄ excize. K ostatnĂm terapeutickĂ˝m moĹžnostem patĹĂ radioterapie, aplikace imiquimodu, 5-fluorouracilu, kyretĂĄĹž, elektrokauterizace, kryoterapie, ablace laserem, fotodynamickĂĄ lĂŠÄba systĂŠmovĂĄ terapie hedgehog inhibitory. Kazuistika popisuje pĹĂpad pacienta s recidivujĂcĂm infiltrativnĂm bazaliomem na Äele vpravo, lĂŠÄenĂŠho chirurgickou excizĂ, radioterapiĂ cĂlenou systĂŠmovou lĂŠÄbou - vismodegib.
منابع مشابه
Vismodegib (erivedge) for advanced Basal cell carcinoma.
Vismodegib (Erivedge) for advanced basal cell carcinoma.
متن کاملEfficacy and safety of vismodegib in advanced basal-cell carcinoma.
BACKGROUND Alterations in hedgehog signaling are implicated in the pathogenesis of basal-cell carcinoma. Although most basal-cell carcinomas are treated surgically, no effective therapy exists for locally advanced or metastatic basal-cell carcinoma. A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among pati...
متن کاملVismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma
© 2014 Harborside Press® Skin cancer is the most common cancer type in the United States, affecting more than 3 million people nationally (Cirrone & Harris, 2012). Basal cell carcinoma (BCC) and squamous cell carcinoma are the two main types of nonmelanoma skin cancer, while the more serious form, melanoma, is in its own category. An estimated 80% of nonmelanoma skin cancers are BCCs (Sekulic e...
متن کاملVismodegib for locally advanced basal cell carcinoma in a heart transplant patient.
IMPORTANCE Immunosuppressed patients with solid organ transplants have an increased risk for nonmelanoma skin cancer. Vismodegib has been reported to be effective for select locally advanced or metastatic basal cell carcinomas. However, there is no data documenting the use and safety of vismodegib in immunosuppressed organ transplant patients. OBSERVATIONS We describe a 78-year-old white man ...
متن کاملTargeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
Basal-cell carcinoma is a commonly occurring skin malignancy that has the potential to progress into locally invasive or resistant disease, as well as spread distantly. Due to advances in the molecular understanding of the disease over the last two decades, it has been discovered that the Hedgehog pathway plays an important role in the pathogenesis of this disease and can be exploited as a trea...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Onkologie
سال: 2021
ISSN: ['1803-5345', '1802-4475']
DOI: https://doi.org/10.36290/xon.2021.026